Efficacy and safety analysis of prucalopride in refractory chronic constipation cases in a tertiary care hospital in Eastern India: A randomized, single-blind, placebo-controlled study.

Indian J Pharmacol · 2023 · PMC10204899 · PMID 36960515

Europe PMC DOI

hedged sentence

0.0010

closest p · 0.0× alpha

0.0010

boldest claim

The sentences

highly significantP ≤ 0.001actually significant

The response rates among patients, when followed through 4–8 weeks, were highly significant ( P ≤ 0.001) in the prucalopride arm (42%) than placebo (17%).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.